January 09, 2026
U.S. Patent and Trademark Office Director John Squires on Friday designated four decisions on discretionary denials at the Patent Trial and Appeal Board precedential and another nine informative.
October 02, 2025
The Patent Trial and Appeal Board has ended Amgen Inc.'s challenge to a now-disclaimed patent covering Bristol-Myers Squibb Co.'s blockbuster cancer drug Opdivo, and denied Bristol-Myers' request to pursue a replacement patent.
July 25, 2025
Acting U.S. Patent and Trademark Office Director Coke Morgan Stewart issued just eight discretionary denial decisions over the last week, including one that addressed arguments tying in the Biologics Price Competition and Innovation Act for the first time.